Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

Eli Lilly announced results from a late-stage trial showing its obesity drug Foundayo reduced symptoms of obstructive sleep apnea in adults with obesity. The company plans to file for U.S. Food and Drug Administration approval by the end of 2026 for use in treating moderate-to-severe obstructive sleep apnea.

• CNBC — Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

Next story